Welcome to the Newron Pharmaceuticals website.
We are a clinical-stage biopharmaceutical company. Our shares are listed on the SWX Swiss Exchange (NWRN). Our mission is to discover, develop and commercialise novel drugs to treat diseases of the Central Nervous System (CNS) and pain.
Discovering and developing innovative therapeutics for CNS disorders
About Us
BoD
Rolf Stahel has been the Chairman of the Board since May 2004. Mr. Stahel, a Swiss national, has a degree in Business Studies from KSL, CH and has attended the Advanced Management Programme at Harvard Business School.
Luca Benatti, the Company’s Managing Director and Chief Executive Officer since 1998, founded Newron in 1998 along with Dr. Ruggero Fariello and Dr. Patricia Salvati.
Francesco Parenti, a Director since 1999, holds a Ph.D. in biological sciences from the University of Milan and has conducted post doctoral research at Yale University.
Hervé Guérin, a director since November 2006, has 30 years of pharmaceutical management experience.
Renee Aguiar-Lucander, a director since 2006, is a Partner in the venture capital group of 3i Group Plc, a leading private equity and venture capital firm with about $10bn of assets under management.
Hans-Joachim Lohrisch, a Director since 1999, holds a doctorate in Organic Chemistry from Bonn University.
Patrick Langlois is presently General Partner of PJL Conseils, a consulting firm in Healthcare.
Ragnar Linder is CEO of Pygargus AB, a CRO acting in the Scandinavian region.
Professor Moehler was the first director of the Swiss National Center of Neuroscience Research (2000-2004), of which he is presently vice-director.